Organization
TYK Medicines
12 clinical trials
Clinical trial
A Phase II, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of TY-9591 Tablets in Patients With EGFR-Mutated Non-small Cell Lung Cancer With Brain or Leptomeningeal MetastasesStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
This is a Single-center, Two-sequence, Open-label, Two-cycle Drug-drug Interaction (DDI) Study in Healthy Subjects. To Evaluate the Effects of Itraconazole Capsules, a Strong Inhibitor of CYP3A4, and Rifampicin Capsules, a Strong Inducer, on the Pharmacokinetics of TY-9591 Tablets After a Single Oral DoseStatus: Recruiting, Estimated PCD: 2024-07-08
Clinical trial
A Phase III, Randomised, Double-blind, Multi-center Study to Assess the Efficacy and Safety of TY-9591 Tablets Versus Osimertinib as First Line Treatment in Patients With EGFR-sensitive Mutation, Locally Advanced or Metastatic Non Small Cell Lung Cancer.Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Phase I/II Study of Oral TY-1091 in Adult Patients With Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, RET-Mutation Medullary Thyroid Cancer, and Other Tumors With RET AlterationsStatus: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase Ia/Ib, Multicenter, Open-label Study of TYK-00540, Administered Orally in Adult Patients With Locally Advanced/Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2026-12-05
Clinical trial
A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of TY-302 Capsules in Patients With Advanced Solid Tumors in ChinaStatus: , Estimated PCD: 2023-05-01
Clinical trial
Studies to Compare the Pharmacokinetics of TY-9591 Tablets and Osimertinib Mesylate Tablets After a Single Fasting Administration and Determine the Effect of Food on the Pharmacokinetics of TY-9591 Tablets in Healthy VolunteersStatus: Completed, Estimated PCD: 2021-09-09
Clinical trial
Phase I, Open-label, Single-arm Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of TY-9591 Tablets in Advanced NSCLC Patients With Epidermal Growth Factor Receptor( EGFR) Positive MutationStatus: Completed, Estimated PCD: 2023-03-03
Clinical trial
A Phase I, Multicenter, Open-label Study of TY-2136b, Administered Orally in Patients With Advanced or Metastatic Solid Tumors Harboring ALK, ROS1 or NTRK1-3 AlterationsStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
[14 C] Study on Mass Balance of TY-9591 in Healthy Chinese Adult Male SubjectsStatus: Recruiting, Estimated PCD: 2024-03-15
Clinical trial
A Phase I, Multicenter, Open-label Study of TY-2699a, Administered Orally in Adult Patients With Locally Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
A Phase II Study of TY-9591 Tablets in Patients With EGFR-Mutated Non-small Cell Lung Cancer With Brain MetastasesStatus: Recruiting, Estimated PCD: 2025-06-30